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Abstract
Interleukin-4 (IL-4) and IL-13 are the only cytokines known to bind to the receptor chain IL-4Ra. Receptor sharing by these two
cytokines is the molecular basis for their overlapping biological functions. Both are key factors in the development of allergic
hypersensitivity, and they also play a major role in exacerbating allergic and asthmatic symptoms. Knowledge of structure and function of
this system has allowed the development of inhibitors that block the interaction between the cytokines and their shared receptor. Mutational
analysis of IL-4 has revealed variants with high-affinity binding to IL-4Ra but no detectable affinity for the second receptor subunit, which is
either gc or IL-13Ra1. These IL-4 antagonists fail to induce signal transduction and block IL-4 and IL-13 effects in vitro. IL-4 antagonists
prevent the development of allergic disease in vivo and an antagonistic variant of human IL-4 is now in clinical trials for asthma. Detailed
knowledge of the site of interaction of IL-4 and IL-4Ra has been gained by structure analysis of the complex of these two proteins and
through functional studies employing mutants of IL-4 and its receptor subunits. Based on these new data, the hitherto elusive goal of
designing small molecular mimetics may be feasible.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introducing IL-4 and IL-13
1.1. Atopic diseases arise due to untimely production of IL-4
Immunologists are hotly debating why atopic diseases like
allergies and asthma are increasing in industrialized coun-
tries. Social, medical, genetic, and environmental factors all
influence the development of allergic sensitivity [1–3]. On a
mechanistic level, an explanation could be offered by point-
ing out that production of interleukin-4 (IL-4) is directing the
immune system toward TH2-dependent allergic reactivity
[4–6], and in consequence, the rise in atopic diseases would
be explained by an increased tendency of the immune system
to produce IL-4 in response to inappropriate stimuli. Rather
than debating the causes of this phenomenon, we will focus
here on strategies for the inhibition of IL-4. Blocking IL-4
could introduce a completely new range of allergy therapeu-
tics affecting the cytokine network.
Therapeutic application seems feasible since IL-4 is not
only critically important for TH2 cell differentiation at the
beginning of an immune response, but is also responsible for
downstream events leading to differentiation and activation
of effector cells. IL-4 induces class switching to IgE and IgG4
in man, and to IgE and IgG1 in mouse [7,8]. It induces
expression of adhesion molecules like VCAM-1 [9–11], TH2
cytokines like IL-5, IL-6, and IL-9 [5,12], and chemokines
like eotaxin-1, -2, and -3 [13–15]. IL-4 can also prime mast
cells [16] and basophils [17], leading to enhanced activation
of cells during allergic challenge. This wide range of effects
suggests that even in ongoing disease, IL-4 inhibition could
still be beneficial.
1.2. IL-13 enhances clinical parameters in allergy and
asthma
IL-13 shares a receptor with IL-4 (see below) and is, for
this reason, able to induce nearly all responses generated by
IL-4 [18,19]. An exception is the IL-4-dependent differ-
entiation of uncommitted TH cells to the TH2 phenotype,
where IL-13 usually cannot replace IL-4 as a differentiation
factor [5,12]. However, IL-13 is produced for a longer period
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of time than IL-4, and seems to be particularly important for
ongoing atopic and asthmatic diseases [20–24]. Experiments
in mice have indeed shown that the selective inhibition of IL-
13 is therapeutically more efficient in asthma models than the
inhibition of IL-4 [25,26]. The homology (similarity)
between both cytokines is as low as about 25% on the amino
acid sequence level [27], which makes it unlikely that any
single antibody or similar agent could neutralize both of
them. Nevertheless, if receptors are shared by both cytokines,
it ought to be possible to find a single inhibitor for both.
1.3. The IL-4 and IL-13 receptor system
For signal transduction, both IL-4 and IL-13 require the
same receptor subunit, IL-4Ra. This protein is part of the
functional heterodimeric receptor complex for either cyto-
kine. It organizes signal transduction through signaling
molecules associated with its large intracellular domain [6].
Signalling is initiated by recruiting and binding of the ligand
to a second receptor subunit, which can be either gc (type 1
receptor) or IL-13Ra1 (type 2 receptor). Type 1 receptor
complexes can be formed only by IL-4, not by IL-13, and
appear to be responsible for signalling in T-cells, which do
not express functional IL-13Ra1. Type 2 receptor complexes
can be formed by either IL-4 or IL-13, and they are activated
by both ligands [6]. A difference between the two ligands is
that IL-4 contacts first IL-4Ra and then IL-13Ra1, a
sequence of events which is reversed for IL-13. Nevertheless,
the resulting dimeric receptor subunit assembly is identical.
2. Therapeutic prospects for IL-4/IL-13 inhibitors
2.1. Selecting a target
In this review, we will not deal with strategies that are
based on the interference with the production of allergy-
associated cytokines, or on the blockage of specific intra-
cellular signalling components which are activated through
cytokine receptors. Rather, we will focus on dealing with
these cytokines as they are. Once IL-4 and IL-13 have been
produced during allergic sensitization or upon challenge
with allergen, inhibition of the receptor–ligand interaction
may offer the most straightforward approach to interfere
with the biological effects of the cytokines. Either the
ligands or the receptor subunits could be targets. Inhibition
is selective for one cytokine if the ligands are targeted. Such
an approach, a humanized antibody against IL-4 (Protein
Design Labs and GlaxoSmithKline), is currently undergoing
phase II clinical trials. Blocking gc is problematic since this
receptor chain is also used by IL-2, IL-7, IL-9, IL-15, and
IL-21 [28,29], which implies that severe side effects must be
anticipated. Loss of functional gc leads to a severe com-
bined immunodeficiency (X-linked SCID) due to the lack of
IL-7 signals during lymphopoiesis [30,31]. IL-13Ra1
appears to be a suitable target since its inhibition would
interfere with effector cell activation, but presumably not
with TH1/TH2 differentiation. An interesting candidate is a
high-affinity binding protein for IL-13, IL-13Ra2, described
from man [32] and mouse [33], which does not form signal-
competent receptor complexes [18,34,35]. A soluble variant
of the murine binding protein is a potent inhibitor for IL-13
in mice [25]. Finally, blocking IL-4Ra would lead to a
complete inhibition of both IL-4 and IL-13 signalling [36].
Indeed, mice lacking a functional gene for this receptor
subunit fail to respond to either cytokine and are severely
impaired in TH2-associated immune responses in models of
parasite infections and allergies [37–43].
2.2. How to inhibit cytokines
2.2.1. Cytokine overdose
Some cytokine receptors are inhibited by high doses of
their specific ligand, which means that the same molecule can
have agonistic and antagonistic effects. An example is the
growth hormone, where high levels of ligand lead to saturat-
ing formation of 1:1 complexes of ligand and receptor,
leaving no free receptor molecules available for receptor
dimerization [44,45]. This principle can only be applied to
cytokines binding to homodimeric receptors (like the growth
hormone or erythropoietin), and is not feasible for hetero-
dimeric receptor complexes as found in the IL-4/IL-13
system. Nevertheless, the observation indicates that preven-
tion of receptor dimerization is a suitable way to disrupt
signal generation and inhibit cytokine effects.
2.2.2. Inhibitory antibodies
Protein–protein interaction is prevented by specific anti-
bodies binding at or near the interaction surfaces, where they
are precluding access of the natural binding partner. Inhib-
itory antibodies may be directed against the ligand or against
the receptor. Inhibitory antibodies against IL-4 [46–49] and
IL-4Ra [50,51] have been developed and were efficient in
cellular assays and in mouse models of parasite infection and
allergy. It should be noted that antibodies against these two
molecules are not functionally equivalent, since only the
latter one inhibits IL-13 as well as IL-4. More surprising is
the observation that anti-IL-4 antibodies can increase the
biological effects of IL-4 [52]. Binding to such an antibody
will of course prevent an IL-4 molecule from contacting the
receptor, but this inhibition is not irreversible. Cytokine and
antibody may dissociate again, with kinetics depending on
the off-rate for the specific cytokine–antibody pair. Antibody
binding prolongs the serum half-life of IL-4 by slowing down
its renal clearance and by protecting the cytokine from
proteolytic digestion. In most circumstances, inhibitory
anti-IL-4 antibodies are net inhibitors, physiologically, but
this cannot be taken for granted and the specific parameters of
an experimental setup have to be considered. In contrast,
blocking IL-4Ra is always inhibitory unless a conscious
effort is made to induce homodimerization of the receptor,
which may lead to unphysiologic activation [53–55].
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2.2.3. Soluble receptor domains
The extracellular domains of cytokine receptors are
produced biologically by shedding or through specific
mRNAs generated by differential splicing [56]. It has been
suggested that these soluble receptor variants may play a
role in the regulation of cytokine activity. The application of
soluble receptor-derived binding proteins offers the advant-
age that these are physiological proteins that should not
elicit an immune response. A soluble variant of IL-4Ra
binds IL-4 with an affinity that is lower only by a factor of
2–4 than for the heterodimeric receptor. The soluble bind-
ing protein is therefore well able to compete with the cell-
bound receptor for its ligand and is highly efficient in
blocking the effects of IL-4 [57–60]. However, soluble
IL-4Ra does not bind IL-13 to a measurable extent and
under some circumstances may potentiate IL-4 effects due
to the same mechanism as observed for inhibitory anti-IL-4
antibodies [57,58,61]. A soluble variant of IL-4Ra is now
undergoing clinical trials for application in the therapy of
allergic asthma [62,63].
2.2.4. Cytokine antagonists
Cytokine antagonists are designed by mutating a binding
site with the intention to create a variant that is still able to
bind one receptor subunit, but not the other one. Antagonistic
mutants cannot activate the receptor and are highly specific
inhibitors. In the case of IL-4, mutation of amino acids in the
binding site for gc leads to the creation of antagonistic
variants [64,65]. Cross-linking experiments have confirmed
that these antagonists bind to IL-4Ra as predicted, but not to
the second receptor subunit [66].
Initially, three amino acids located close to the C-terminus
were identified as particularly sensitive toward exchanges:
R121, Y124 and S125 [64,65]. Simultaneous mutation of
R121 and Y124 to aspartic acid residues (R121D/Y124D)
creates a protein that has a high binding affinity for IL-4Ra,
no detectable biological activity, and which completely in-
hibits both IL-4 and IL-13 signalling [50].
The analogous amino acids in mouse IL-4 are Q116 and
Y119. The variant Q116D/Y119D corresponding to the
human antagonist is a complete inhibitor for IL-4 and IL-13
[39,67]. Inhibitory activity is also created by the single point
mutation Y119D [68] or by truncating mouse IL-4 after
residue 118 [69].
Cytokine antagonists can be designed by introducing very
small changes into the original molecule. For human IL-4, the
powerful antagonist R121D/Y124D retains 127 of the 129
amino acids of the natural protein. This does not absolutely
prevent immune reactions against the new epitope, but good
tolerance can nevertheless be expected.
2.2.5. Small molecular mimetics
Proteins offer the advantage of evolution-selected bind-
ing specificity, but are pharmaceutical agents of limited
applicability. Mass production of recombinant proteins is
expensive and difficult, proteases may quickly dispose of
the carefully designed agent, and oral application is still
impossible. Small synthetic molecules that mimic the pro-
tein binding surface and maintain a high binding affinity
would be an attractive alternative. So far, no synthetic
substance has been identified which could be used in the
IL-4/IL-13 system, but progress in resolving the structures
of IL-4 and IL-4Ra combined with functional analysis may
facilitate such attempts in the future [70].
3. Structural and functional analysis of the IL-4/IL-13
receptor system
3.1. The structure of IL-4
IL-4 is one of the small four-helix-bundle cytokines
[71,72] that are characterized by antiparallel juxtaposed
helices A, C, B, D, and two long end-to-end loops, loop
AB and CD, which are connected by a short h-sheet packed
against helices B and D (Fig. 1a) [73–78]. The conserved
exon boundaries present in the IL-4 gene are also indicated in
Fig. 2. Helix A, the AB loop, the helix BC hairpin, and the
loop CD plus helix D are encoded by four different exons. An
invariant disulfide bond (C46/C99) seems to stabilize the
helix BC hairpin. IL-4 has two binding epitopes: The binding
epitope for the high-affinity receptor chain IL-4Ra is located
on the helices A and C [65,79], whereas the binding site for
the low-affinity receptor chains, both gc and IL-13Ra1, is
located on helices A and D [65,80].
IL-4 is found exclusively in mammals. Nevertheless, the
divergence of the amino acid sequence among species is
high. A large part of helix C present in the primate protein is
absent in rodents and even more is deleted in the sequences
of IL-4 from cattle, pig, and cat (Fig. 2). Amino acid differ-
ences among human and primate IL-4 proteins are confined
mainly to helix A (exon 1) near the binding epitope for the a
receptor chain.
Biological activity of IL-4 is species specific in many
instances. Murine IL-4 does not interact with the human
IL-4Ra chain at physiological concentrations [67]. This is
remarkable, since the main binding determinants (E9, R53,
Y56, and R88) for the a chain are conserved (Fig. 2). As
discussed below, binding specificity between IL-4 and IL-
4Ra seems to be modulated by side chains that do not
contribute significantly to the binding [81]. Thus, mis-
matches disturbing the complementarity of the contact
epitopes most likely broaden binding specificity. The helix
AC face of human IL-4 accumulates a large positive
charge due to several basic residues, namely K12, R53,
R75, K77, R81, K84, R85, and R88 (Fig. 1b). In contrast,
the IL-4Ra binding epitope contains a series of acidic
residues (Fig. 3b). This charge complementarity will
induce electrostatic steering during the association of IL-
4 and IL-4Ra [82] (Fig. 4), and in consequence, the
association rate constant kass is exceedingly high (>10
7
M 1 s 1). Only two of these basic amino acids are
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conserved among the known IL-4 sequences of all species.
As a result, the association rates for binding of IL-4 to IL-
4Ra should be lower in other species, as seen for mouse
IL-4 with a kass of < 10
7 M 1 s 1 [67].
3.2. The structure of IL-4Ra CHR
The extracellular binding domain of IL-4Ra (IL-4Ra
CHR) represents the minimal version of a typical cytokine-
Fig. 1. (a) Ribbon diagram of human IL-4. The four-helix bundle with the up-up-down-down topology is a typical member of the short-chain cytokine family.
The exon-intron boundaries found for IL-4 are confined to secondary structure elements. Exon 1 encodes for helix A (blue), exon 2 for the long loop AB
(green), exon 3 comprises helices B and C (orange) and exon 4 encodes the second long loop CD and helix D (red). The invariant disulfide bond between
Cys46 and Cys99 is shown in yellow. (b) Electrostatic potential of IL-4. The orientation of the molecule is the same as in (a). The surface is color-coded
according to its electrostatic potential (intense blue: + 2.5 kT/e; intense red:  2.5 kT/e). The electrostatic potential was calculated using the program GRASP
(full charges, salt concentration 150 mM). The figure shows the strong positive potential of the binding interface for the IL-4Ra chain, also called AC face.
Fig. 2. IL-4 is found only in mammals. The sequences for mature IL-4 were aligned using the programs ClustalW, PILEUP (GCG version 9.1) and Jalview
(http://www2.ebi.ac.uk/fmichele/jalview/contents.html). The amino acid type is color-coded using the Taylor color scheme. The intensity of the color was
manipulated to show the degree of conservation for each residue position; sites showing intense color are exhibiting a higher degree of conservation. Secondary
structure elements (helices and sheets as determined from the crystal structure of human IL-4) are indicated together with the color-coding for the intron/exon
boundaries (see also Fig. 1a). The main binding determinants for the IL-4Ra chain are marked by black triangles (AC face), for the gc receptor subunit, open
circles are used (AD face).
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binding homology region (CHR) [83]. Two fibronectin type
III (FnIII) domains, each about 100 residues long, are
connected by a short linker segment (Fig. 3a). The N-
terminal FnIII domain D1 containing the conserved disul-
fide bonds exhibits the h-type of an immunoglobulin fold
[84]. The second FnIII domain D2 does not contain any
disulfide bonds and exhibits the FnIII topology of type s
[84]. In addition, domain D2 includes the wsws motif,
typical for the cytokine receptor type I family [83].
The elbow region between the two FnIII domains is
dominated by the long inter beta-sheet loops L2 and L5 that
are flanked by loops L1 and L3 in the first FnIII domain and
by loop L6 in the second. The linker L4 connecting the two
FnIII domains is buried underneath the contacting loops and
is not accessible to the cytokine ligand. Sequence comparison
of the loops in the elbow region of the CHR of IL-4Ra,
hGHbp, EBP, gp130, andG-CSFbp reveals a high diversity in
length as well as amino acid composition. This reflects the
specificity of cytokine recognition as well as different bind-
ing modes, that is, low- or high-affinity binding and AC- or
AD-face interaction.
Since the three-dimensional structure for the free IL-4Ra
chain has not been determined so far, we can only speculate
about possible changes of the structure of the receptor upon
binding to its ligand. However, for two other members of the
cytokine receptor superfamily, erythropoietin receptor (EP-
OR) and gp130, the structures for the free receptor as well as
for the receptor in complex with the ligand have been
determined. The structure of the ligand-binding domain
(CHR) of the receptor gp130, which is shared among IL-6,
CNTF, LIF, oncostatin, and IL-11, has been determined in
free form and bound to its ligand IL-6 [85,86]. The super-
Fig. 3. (a) Ribbon diagram for IL-4Ra CHR. The modular architecture of IL-4Ra CHR is shown. The two fibronectin type III domains are color-coded in blue
(FnIII domain 1) and orange (FnIII domain 2), and loop regions in contact with the ligand IL-4 are shown in green. Due to lack of electron density, no coordinates
are available for the loop regions from residue 107 to 112 and 163 to 169 in the second FnIII domain. (b) Electrostatic potential map of IL-4Ra CHR. The surface
representation of IL-4Ra CHR in its bound form is shown color-coded by the electrostatic potential as calculated in GRASP (red:  2.5 kT/e; blue: + 2.5 kT/e).
The binding site for the ligand IL-4 exhibits a strong negative potential complementary to the positive potential of the ligand IL-4 itself.
Fig. 4. Electrostatic steering is the cause for an extremely fast association. The strong complementary charge distribution of the ligand IL-4 and the receptor
ectodomain IL-4Ra lead to an electrostatic steering effect. At first, the strong dipoles of both molecules cause a ‘‘pre-alignment’’ (a), so that the dipoles of both
molecules are aligned parallel (b). The pre-oriented molecules then associate with a very fast on rate (b) to yield the final complex (c).
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imposed coordinates for the free and bound form of the gp130
molecule show almost no change in either the side chain
conformation or in the hinge angle between the FnIII mod-
ules, suggesting that the structural motif of cytokine receptors
is rather rigid. However, a detailed analysis of the structure of
free gp130 reveals some possible bias; two receptor mole-
cules form a kind of dimer in the crystal lattice with major
contacts in the binding region of IL-6. One might therefore
speculate that this dimer simulates the binding of IL-6, with
the consequence that the similarity of the free and bound form
of gp130 could be actually caused by a crystal packing
artefact. The structure of the erythropoetin receptor (CHR)
was also determined in free and bound (to erythropoietin and
also to an EPO mimetic) conformation [87–89]. Similarly to
gp130, the structures for the CHR in its free and bound form
can be superimposed yielding deviations for the coordinates
of the backbone atoms of less than 1 A˚. The major differences
are in the conformation of a few side chains in the binding
region, probably due to plasticity to allow for adaption to the
different ligands (native EPO and peptide mimetic). From
these two examples, it must be assumed that the CHR is a
rather rigid motif in general. The NMR studies, which could
give a direct insight into the dynamical behaviour of the
modular motif, focus unfortunately on isolated FnIII modules
of the receptor ectodomains and thus cannot answer the
question of flexibility between the two FnIII modules
[90,91]. In the case of the IL-4:IL-4Ra CHR complex,
multiple interactions between side chains of the two FnIII
domains and the compact packing of the loops in the hinge
region also suggest that the CHR of IL-4Ra acts rather like a
rigid body [81].
The charge distribution of IL-4Ra CHR presented in Fig.
3b shows a concentration of acidic negatively charged
residues in the elbow region which forms the contact with
IL-4. Mutational analysis and model calculations indicate
that these complementary charge patterns enhance the affinity
of the complex of IL-4 and IL-4Ra CHR by about 10-fold
due to an increase in the on-rate constant of complex
formation [82,92]. The dramatic effect of electrostatic steer-
ing becomes obvious when the association rate for hGH and
its receptor is compared to the much faster association for the
IL-4/IL-4Ra CHR system. The hGH-induced homodimeri-
zation of its receptor chains requires a symmetrical charge
distribution, which leads to two possible encounter com-
plexes [82]. In addition, with the lower overall charge, the
lack of a strong dipole character results in a much lower on-
rate of 3.5 10 5 M 1 s 1 [82,93,94].
3.3. High-resolution analysis of the binding epitopes in the
IL-4/IL-4Ra CHR complex
Large contact areas of IL-4 and IL-4Ra CHR comprising
17–18 residues and an area of more than 1000 A˚2 in each
protein become buried upon complex formation. The land-
scapes of the structural epitopes as established by X-ray
analysis of the complex reveal knobs and holes on both sides
of the interface, as well as a mixed pattern of charged, polar,
and hydrophobic residues [81] (Fig. 5a–d). The hGH/hGHbp
paradigm would have predicted that the hydrophobic side
chains V69 and Y127 of the IL-4 receptor, which protrude at
the center of the contact area, represent a hot spot of hydro-
phobic binding energy [94–96]. The central position of both
residues in the loop L2 and L5 corresponds to the location of
the central binding determinants W104 and W168 in hGHbp
[95]. Mutational analysis of both IL-4 and IL-4Ra CHR
proved, however, that this prediction is wrong [92]. Mutation
of the residues V69 and Y127 of IL-4Ra CHR to alanine
reduced the binding affinity to IL-4 only about 50-fold. A
much larger decrease in affinity ranging from 200- to 1000-
fold was found when either residue D72 or Y183was mutated
(Fig. 5d). The receptor mutants D72A and D72N exhibit
dissociation constants Kd that are 1500- and 2200-fold larger
than that of the wild-type IL-4Ra CHR. This indicates that
the negatively charged carboxylate group of D72 is required
for binding (Fig. 6a). Substitution of residue Y183 in the
mutants Y183A and Y183F results in a 500- and 200-fold
increase in Kd, indicating the importance of the tyrosine
hydroxyl group for IL-4 binding (Fig. 6b).
Mutational analysis of IL-4 confirmed that two polar
interactions provide most of the binding energy in the IL-4/
IL-4Ra CHR complex. The side chains of the IL-4 residues
E9 and R88 are the main binding determinants [97] (Fig. 5c).
Disruptive mutations in the variants E9Q, R88A, or R88Q
lead to a 100- to 200-fold reduced binding affinity, respec-
tively [65,97]. X-ray analyses of the free mutant proteins E9A
[98] and R88Q [78] prove that there are no structural alter-
ations causing the decrease in binding affinity. The crystal
structure of the complex reveals that residue R88 of IL-4 can
form an ion pair with residue D72 of IL-4Ra CHR (Fig. 6a),
and residue E9 of IL-4 can accept three hydrogen bonds from
the receptor residues Y183, Y13 (hydroxyl groups) and S90
(main chain amide group) (Fig. 6b) [81].
The combined mutational and structural analysis also
explains the large contribution of these two residues to the
interaction of IL-4 and IL-4Ra CHR (hot spots of binding
energy). Both interacting side chains of E9 and R88 are
surrounded by a shell of minor binding determinants that are
mainly hydrophobic (Fig. 5a,b). This kind of binding motif
has been termed ‘‘avocado cluster’’ [81], since an avocado
fruit has also a core that is surrounded by a hydrophobic layer.
The hydrophobic shell of ‘‘avocado cluster’’ I consists of the
residues I5, K12, T13, and N89 of IL-4 and residues Y13,
A71, Y183, andY127 of IL-4RaCHR (Fig. 5a,b). The core is
the hydrogen bond network emanating from the carboxylate
group of IL-4 E9 (Fig. 6b). In ‘‘avocado cluster’’ II, the ion
pair between IL-4 R88 and residue D72 of IL-4Ra CHR is
shielded by residues R53, Y56, andW91 of IL-4 and residues
L39, F41, and V69 of the IL-4 receptor a-chain (Figs. 5a,b
and 6b). It is therefore conceivable that the polar interactions
are reinforced by the low dielectricity of the microenviron-
ment. Also, it is interesting to note that the contribution in
binding energy does not correlate with the contribution of
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surface area by a particular residue (Fig 5e,f). Several re-
sidues, for example, I5, K12, R81, and R85 that are a major
part of the contact interface contribute only little (about 0.2–
1.6 kcal mol 1) to the total binding energy of about 13.5 kcal
mol 1. The probable cause could be either in the entropy cost
of fixing flexible side chains or in the nature of the inter-
Fig. 5. Comparison of structural and functional epitope. The surface representation for the structural epitopes for IL-4 (a) and IL-4Ra CHR (b) is shown.
Negatively charged residues are shown in red (Asp, Glu), positive ones in blue (Arg, Lys), green color represents hydrophobic amino acids (Ala, Gly, Ile, Leu,
Val), aromatic residues in magenta (Phe, Tyr, Trp), polar residues are shown in orange (Asn, Gln, His, Ser, Thr). The structural epitope can be divided into three
‘‘avocado clusters’’. The IL4:IL-4Ra CHR complex can be obtained by rotating the ligand IL-4 around the y-axis by 180j, so that equally numbered clusters
are on top of each other. In comparison to the structural epitopes, the functional epitopes are shown in (c) and (d). The energy contribution of each residue was
determined by exchange of the respective residue to alanine and measurement of the binding capabilities of the mutant using BIAcore methodology. The color
code for the energy contribution is given in (c). (e,f) The residues of IL-4 and IL-4Ra CHR are color-coded according to their contribution to the surface area in
the contact interface. As can be seen clearly, contribution of a large area does not correlate with the binding energy supplied by the respective residue. Residues
E9 (cluster I) and R88 (cluster II) are clearly the main determinants for the binding energy, despite of the fact that the amount of surface area contributed by
residue E9 is smaller than for other less ‘‘important’’ residues, for example, I5, K12, or R85.
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actions formed, for example, hydrophobic contacts and
hydrogen bonds.
In conclusion, high-resolution structural and functional
analysis of the IL-4/IL-4Ra CHR interface reveals a sophis-
ticated anatomy and substructure of the binding epitopes. A
total of three different types of binding elements can be
discriminated. First, charge complementarity contributes a
factor of about 10 to the affinity constant KA (1–1.5 kcal
mol 1 to the free energy of binding) by increasing the rate of
association. Second, ‘‘avocado cluster’’ I contributes a factor
of 104- to 105-fold to the affinity constant Kd (about 6 kcal
mol 1). Third, about the same contribution is made by
‘‘avocado cluster’’ II. Assuming that the contributions add
up linearly, the sum of all three binding elements would yield
a total free energy of binding of 13.5 kcal mol 1, correspond-
ing to a dissociation constant Kd of 100 pM. This value is in
remarkably good agreement with the observed Kd of 100–
200 pM for IL-4/IL-4Ra binding. Recently, it has been shown
that the binding affinity of residues in the two different
‘‘avocado clusters’’ of IL-4 is indeed additive, whereas the
binding affinity of residues within one cluster is cooperative
[92]. Receptor double mutants with mutations in each cluster
exhibit a decrease in binding affinity that corresponds to the
sum of the decrease found for the respective single mutants.
In contrast, double mutations within one cluster did not show
additivity of the contributions found for the single mutants.
3.4. Binding of the second receptor chain
3.4.1. IL-4 utilizes two different low-affinity receptor chains
The high-affinity binding of IL-4 to the receptor IL-4Ra
chain has been analyzed in detail. Structural (contact area)
and functional (energy contribution of individual residues)
epitopes are well characterized. Thermodynamic and kinetic
parameters of IL-4 interaction with IL-4Ra CHR are almost
identical to results from experiments utilizing the complete
IL-4Ra receptor expressed on whole cells. However, bind-
ing of the second receptor subunit that is either gc [99,100]
or IL-13Ra1 [101–104] is more difficult to analyze. For
cells expressing only gc or IL-13Ra, no binding of IL-4 can
be observed even at concentrations as high as 100 nM [105].
The receptor subunit IL-4Ra would be fully saturated at this
ligand concentration, considering the small dissociation
constant of 100 pM for the IL-4/IL-4Ra interaction. The
binding affinity of the gc ectodomain to IL-4 was deter-
mined using surface plasmon resonance technology to about
150 AM. The affinity is increased by a factor of 50 if gc
interacts with the high-affinity complex of IL-4 and IL-4Ra
CHR, yielding a dissociation constant Kd of approximately
3.5–5 AM [80].
Although these results prove that IL-4 can bind directly
to gc, it has to be considered that subnanomolar concen-
trations of IL-4 are quite sufficient for biological activity.
These concentrations are much too low to allow direct
binding of solute IL-4 to gc under physiological conditions.
It was therefore proposed that the ligand-induced dimeriza-
tion of the receptor subunits proceeds in a two-step mech-
anism. In the first step, the solute IL-4 binds to the
membrane-anchored ectodomain of IL-4Ra after a three-
dimensional search reaction. In the second step, the low-
affinity subunit gc performs a two-dimensional search on
the surface of the membrane to find and bind to the high-
affinity complex of IL-4:IL-4Ra. The weak interaction of gc
with the intermediate complex IL-4:IL-4Ra in the micro-
molar range, as was measured by BIAcore experiments,
seems puzzling at first sight, considering that full biological
activity is observed at concentrations as low as 200 pM for
the ligand. However, a likely explanation for this contra-
diction is the sequential nature of the activation mechanism.
The very weak affinity of Kd = 5 AM as determined by the
Fig. 6. Hydrogen bonding pattern for the ‘‘hot spots of binding’’. (a) Residue R88 forms a bi-dentate salt bridge with residue D72 of IL-4Ra CHR. The
shielding of the salt bridge by mainly hydrophobic residues and thus the reinforcement of these hydrogen bonds explains the high energy contribution of this
residue. (b) Similarly, residue E9 of IL-4 is showing a complex hydrogen bond pattern. Intramolecular hydrogen bonds of the carboxylate group of E9 with
residue N89 might pre-orient the side chain of E9 for the intermolecular hydrogen bonds. The carboxylate group of E9 is then capable of forming
intermolecular hydrogen bonds with the main chain amide of S70 and the hydroxyl groups of the tyrosines Y13 and Y183 of IL-4Ra CHR. In addition, K12 of
IL-4 can also form a hydrogen bond with the hydroxyl group of Y13 of IL-4Ra CHR. The large number of possible hydrogen bonds involving residue E9
explains the enormous energy contribution of this single residue.
T.D. Mueller et al. / Biochimica et Biophysica Acta 1592 (2002) 237–250244
BIAcore experiments is likely to be an artificial result of
measurement procedure. In reality, the second binding event
is not a three-dimensional search as it is in the in vitro
measurement but a two-dimensional search on a surface.
Subsequently, a smaller number of translational and rota-
tional degrees of freedom shall lead to an increased binding
affinity in the in vivo (membrane-anchored) situation. The
rate of productive collisions is much larger due to one less
degree of freedom of the diffusion. Additionally, the ‘‘local
concentration’’ of IL-4 on the cell surface is increased upon
binding of IL-4 to the IL-4Ra chain as compared to the
concentration in solution. A density of about 1000 receptor
molecules on a cell surface with a surface area of about 100
Am2 is comparable to a concentration of about 50 nM in
solution. The apparent concentration of IL-4 on the cell
surface is therefore much higher than estimated from the
serum level. In addition, binding of the second receptor
subunit to the 1:1 complex of ligand and high-affinity
receptor subunit is limited to a two-dimensional search in
the plane of the membrane. These considerations may
explain why a relatively low affinity of the second receptor
subunit is still sufficient to achieve receptor dimerization.
3.4.2. Selective antagonists of IL-4
So far, no experimental structural data are available for the
low-affinity complexes of IL-4/IL-4Ra CHR with either the
gc or the IL-13Ra1 receptor chain. However, extensive
mutagenesis studies of IL-4 and also of the gc receptor chain
give insights into the mechanism of recognition and binding
of IL-4 to its low-affinity receptor subunits [106] (T. Hom and
Fig. 7. Selective antagonists for gc and IL-13Ra. Ribbon (a) and surface (b) representation of IL-4. The color-coding represents the loss of binding affinity to
the gc receptor upon mutation to alanine. Red color is used for residues for which mutation to alanine results in almost total loss of binding, whereas orange and
yellow indicate a significant and small change in binding affinity, respectively. (c,d) Same as in (a,b) but for the binding of IL-4 to IL-13Ra. Although the
epitopes are similar in size and location, there are significant differences in utilizing respective residues for the recognition. The main binding determinants of
IL-4 in binding to gc are the residues I11 and Y124, whereas for binding of IL-4 to IL-13Ra, residue R121 is also absolutely required.
T.D. Mueller et al. / Biochimica et Biophysica Acta 1592 (2002) 237–250 245
W. Sebald, unpublished). For the ligand IL-4, antagonists
have been discovered which can selectively inhibit either
signal transduction through the gc (Fig. 7a,b) [65,80] or the
IL-13Ra1 chain (Fig. 7c,d) [107,108] (T. Hom and W.
Sebald, unpublished). The first partial antagonistic mutant
of IL-4 was described in 1991 [109]. Residue Y124 of IL-4 at
the C-terminal end of the fourth helix was replaced with
aspartate, resulting in a mutant protein capable of competing
for binding to IL-4Ra with wild-type IL-4, but reduced to
about 5% ofwild-type activity [64].Mutating further residues
around Y124 also led to partially antagonistic behaviour, for
example, residues R121 and S125 [65]. The double mutant
R121D/Y124D has been shown to be the most effective
antagonist for the interaction with gc, while retaining almost
complete binding affinity for IL-4Ra [50]. Structure analyses
for the partial antagonists Y124D and Y124G proved that the
antagonistic effect is not mediated through a significant
change in structure or loss in structural integrity but rather
through an exchange of the side chain functionality [110].
The observation that negatively charged residues are most
effective in creating an antagonistic mutant supports the
theory of introduction of an electrostatic mismatch in the
binding interface. A more detailed study using alanine
replacement revealed that several residues are used to dis-
criminate for the binding to either gc or IL-13Ra1 (T. Hom
and W. Sebald, unpublished).
The epitope of IL-4 used for binding to gc comprises
residues I11, K12, N15 on helix A and residues E114, K117,
T118, R121, E122, Y124, and S125 on helix D (Fig. 7a,b).
Only three residues are showing a larger decrease in binding
affinity upon mutation to alanine, namely, I11, N15, and
Y124. However, if the interaction with IL-13Ra1 is analyzed,
differences in the contribution of individual residues are
observed, although the size of the functional epitope is very
similar, and in both cases, the dissociation constant is roughly
5 AM. While mutation of residue R121 to alanine does not
alter the affinity to the receptor chain gc to any large extent,
this residue is of significant importance for the interaction
with IL-13Ra (Fig. 7c,d). The interaction of N15 with either
receptor subunit is also of different strengths, although not to
the extent as seen for R121. The observation that several
residues contribute differently to the binding affinity of the
two low-affinity receptor subunits suggests that recognition
and binding of both receptors subunit is different in detail
[107,108] (T. Hom and W. Sebald, unpublished).
3.4.3. The binding epitope of a low-affinity receptor subunit
The binding site of IL-4 on gc was determined by muta-
genesis [106]. Comparison of the IL-4 epitope responsible for
the high-affinity interaction with IL-4Ra with the epitope
determined for the interaction with either gc or IL-13Ra1
suggests that the mechanism of recognition is probably very
different. For the IL-4/IL-4Ra interaction, two charged
residues, E9 and R88, are contributing almost all of the
binding energy, whereas for the much weaker interaction of
IL-4with either gc or IL-13Ra two hydrophobic residues, I11
Fig. 8. Binding epitope for gc. Surface representation of IL-4 (a) and a theoretical model of gc (b) color-coded by the loss of binding affinity upon mutation to
alanine. (a) is identical to Fig. 7b, but shown additionally on that panel to facilitate a comparison of the ligand and receptor epitopes. Residues I11 and Y124
contribute 2–2.6 kcal mol 1 each for the interaction with the receptor subunit gc. (b) Receptor variants I100A, L102A and Y103A in loop L3 as well as
L208A in loop L6 show the largest decrease in binding affinity upon substitution by alanine. An even larger loss in affinity is observed when either cysteine
residues C160 or C209 are mutated, but model building suggests a disulfide bridge between these two cysteine residues which would stabilize the loop
conformation of loops L5 and L6. Therefore, mutation of either one cysteine is likely to cause structural perturbations, resulting in an indirect loss of binding
affinity. Figs. 1–8 were generated using the programs Molscript [128], Jalview (http://www2.ebi.ac.uk/fmichele/jalview/contents.html), Raster3D [129],
DINO (http://www.dino3d.org) and Grasp [130].
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and Y124, are essential (Figs. 7a,b and 8a). Using alanine
replacement, four residues, I100, L102, Y103 (loop L2), and
L208 (loop L6), were identified as major binding determi-
nants (Fig. 8b). Double mutation cycle analysis allowed to
determine possible interaction pairs, indicating that residues
in the loop L2 (I100, L102, Y103) probably interact with
residues Y124 and S125 of IL-4 and residues in the loops L6
(L208, G210) and L5 (L161) probably interact with residues
I11, N15, and R121 of IL-4 (Fig. 8a,b).
The binding determinants of gc for IL-4 appear to follow
the rules for the hydrophobic hot spot of binding as seen for
hGHR [95]. The key residues in hGHR required for binding
of the ligand are W104 and W169 in the loops L3 and L5.
Similar clusters of hydrophobic determinants have been
found in several other type I cytokine receptors, for example,
hEPOR [88], gp130 [111], and hhc (human common h chain)
[112,113]. Two mutant proteins of gc, C160A and C209A,
also showed a dramatic loss in binding affinity (Kd>500 AM).
However, model building suggests that C160 and C209 form
a disulfide bridge that would stabilise the loop conformation
of the binding loops L6 and L5 (T. Mu¨ller, PhD thesis, 1995)
[106,114]. The observed decrease in binding affinity for the
two cysteine mutants is therefore likely to be a result of
structural perturbations, although a participation in direct
binding cannot be ruled out.
Since the gc receptor subunit is shared by the cytokines IL-
2, IL-4, IL-7, IL-9, IL-15, and IL-21 [28,29], it is interesting
to know whether the residues identified for the IL-4/gc
interaction are also playing a similar role in binding the other
cytokines. Residue Y103 was shown to participate in binding
of IL-2 and IL-7, although mutation of the tyrosine to either
alanine or arginine did not exhibit a similarly large effect as
found for IL-4 [115]. Further residues of gc, I100, L102, and
L208, which are all important for the interaction with IL-4,
did not show any significant contribution to the IL-2 and IL-7
interaction in this particular study. However, using the ge-
netic information reported for X-SCID patients [116], mis-
sense mutations of gc are reported for the residues Y103,
L161, L208, and G210, indicating that residues other than
Y103 are also playing an important role in binding of IL-2,
IL-7, and IL-15.
4. IL-4 receptor antagonists in vitro, in vivo and in the
clinic
4.1. Cellular effects of antagonistic IL-4 mutants
Antagonistic IL-4 mutants were initially identified by
their loss of proliferative activity despite seemingly intact
receptor binding. It was subsequently found that mutants
with such a behaviour actually prevented the induction of
cell proliferation by wild-type IL-4, and their antagonistic
potential was recognized [64,65]. Other cellular responses
were later shown to be blocked as well, including phosphor-
ylation of IL-4Ra [117] and Stat6 [107], expression of
CD23 [50,59], and class switching to IgE [59,118,119].
Inhibition of IL-4/IL-13-dependent responses by IL-4 antag-
onists was shown for a wide variety of cell types, since
functional IL-4 receptors are essentially ubiquitously ex-
pressed. The available data indicate that IL-4 antagonists
block all IL-4- and IL-13-dependent responses in all cell
types. This corresponds well with results from transgenic
mice lacking IL-4Ra, which also lacked responsiveness
toward these two cytokines [37–43].
4.2. Animal studies and clinical trials
The value of IL-4 antagonists has been demonstrated in
mice, where the application of antagonists created by mutat-
ing murine IL-4 prevented the development of allergic
reactivity [39]. Typical allergic responses like serum titers
for antigen-specific IgE and IgG1, local cutaneous anaphy-
laxis upon intradermal delivery of antigen, and systemic
anaphylactic shock upon intravenous application of the anti-
gen were absent if mice had been treated with the antagonistic
mouse IL-4 variant Q116D/Y119D along with antigen during
the sensitization protocol [39].
Another murine IL-4 antagonist was created by deleting
the C-terminal amino acids following Q119 [69]. This
antagonist was assayed in an asthma model, where it
inhibited IL-4/IL-13-induced Stat6 phosphorylation and
IL-4/IL-13-induced IgE production in a splenocyte culture
in vitro. Administration during antigen challenge inhibited
the development of airway eosinophilia and acute hyper-
responsiveness. Levels of IL-4, IL-5 and IL-13 in bron-
choalveolar lavage fluid were reduced, as were serum levels
of specific IgE [69]. These data confirm findings of
decreased bronchial hyperresponsiveness and reduced infil-
tration of eosinophils following the application of a human
IL-4 antagonist in a monkey (Macaca fasciculata) model of
allergic asthma (R. Gundel, W. Sebald et al., unpublished).
The antagonistic IL-4 mutant R121D/Y124D has now
entered a phase II clinical trial where it is evaluated for the
treatment of allergic asthma. The positive results from the
animal studies suggest that there is hope for therapeutic
benefits in humans as well.
5. What do we learn from IL-4/IL-13 antagonists for
other cytokines?
Activation of cytokine receptors is achieved by homo- or
heterodimerisation of receptor chains in the cell membrane.
In some cases, for example, for IL-2 and IL-6, a third receptor
chain is used to enhance the affinity for the ligand. So far for
all cytokine systems studied, the mechanism of activation has
been shown to be sequential. The first step involves the
binding of the ligand to its high-affinity receptor, and in the
second step, this intermediate complex interacts with the low-
affinity receptor chain, leading subsequently to signal trans-
duction into the cell.
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Does this mechanism allow us to generate antagonistic
variants in a general manner by blocking the second inter-
action, as demonstrated with the IL-4 receptor antagonists?
One major obstacle is in the binding affinity of the ligand and
its high-affinity receptor chain compared to the affinity for the
whole receptor complex. Although most cytokine receptors
bind their respective ligands with an affinity ofKd = 100–500
pM, the total affinity of binding is rarely dominated by one
receptor subunit as it is for IL-4. Almost all of the binding
affinity (Kd = 100 pM) is generated by the interaction between
IL-4 and its high-affinity receptor chain IL-4Ra. Super-
antagonistic mutants that do not bind to gc at all still exhibit
a binding affinity of Kd = 200–300 pM for IL-4Ra, which is
only lower by a factor 2–3 than for the wild-type protein.
This allows an effective competition of wild-type activity
with the antagonistic mutant. However, in most cases, the
ligand binds to the high-affinity chain with an affinity 100
times lower than was measured for the whole receptor
complex on the cell. Only the additional association with
the low-affinity receptor chain then yields the full-binding
strength.
For example, IL-3 binds to its receptor a-chain with a
Kd = 20–100 nM, while upon association with the common
beta chain hc shared between GM-CSF, IL-3, and IL-5, the
affinity is increased to Kd = 100–500 pM [120]. Similar
differences also occur in the gc family. Since the binding
affinity of IL-2 to the IL-2Rh chain is low, effective
antagonistic variants of IL-2 have not been developed so
far, although structure and sequence comparison of IL-2
and IL-4 suggest a similar binding interface to gc. A
possible solution is the development of so-called super-
agonists, which bind to their first receptor chain with a
much higher affinity. Such mutants have been found in
mutagenesis studies for hGH [121], IL-6 [122,123], and
IL-4 [92]. The difficulty in finding such super-agonists is
that even with knowledge of the structure of the ligand–
receptor complex, a rational design or prediction of such
mutants has so far not been achieved. Nevertheless, it
should be possible to transfer the principle of antagonistic
inhibition from IL-4 to other cytokines by using a combi-
nation of super-agonistic and antagonistic mutations. Sha-
nafelt et al. [124] have shown another nice example of
‘‘molecular medicine’’ by designing a cell-selective IL-2
variant. IL-2 has a great potential as antitumor therapeutic,
but systemic toxicity is a limiting factor in its application.
However, the toxicity effect is mainly confined to the IL-2
activity on NK cells, which express the intermediate
affinity complex comprising IL-2Rh and gc, whereas the
tumor-suppressing activity is mediated by T-cells, which
express the high-affinity receptor consisting of IL-2Ra, IL-
2Rh, and gc. By elegantly modulating the affinity of IL-2
to its IL-2Rh chain, a mutant IL-2 was designed that
preferentially binds to the high-affinity complex [124].
Since this receptor complex resides almost exclusively on
the desired target T cells, the application-limiting toxicity
could be reduced.
6. Structure/function analysis and the prospect for small
molecular mimetics
The development of antagonistic variants of IL-4 that are
now in clinical phase II trials is a nice example for the power
of structure/function analysis and its value in molecular
medicine. The knowledge of the structure of the ligand IL-4
in its free form as well as the structure of the ligand–receptor
complex IL-4:IL-4Ra CHR, together with the information
about the energy contribution of each individual residue,
enabled us to rationally design mini-proteins that mimic the
binding of IL-4 to its IL-4Ra chain. The epitope of IL-4 for
the high-affinity interaction with its a-chain is located on two
antiparallel helices and occupies an area of about 800 A˚2. By
model building, this motif was placed onto the parallel a-
helices of the GAL4 leucine zipper [125] and the newly
designed peptide was synthesized. The synthetic peptides
exhibited binding to IL-4Ra with a Kd of about 5 AM.
Although the affinity would be far too low for therapeutic
purposes, the design of such synthetic peptides clearly shows
that it is in principle possible to design inhibiting analogs that
are highly different from the wild-type protein.
Using peptide libraries and in vitro evolution, a dimeric
peptide-mimetic for erythropoietin was developed which
exhibits agonistic activity in the nanomolar concentration
range [88,126,127]. These results are encouraging, since the
large and relatively flat binding interfaces are very challeng-
ing for the classical computational drug design. However,
minimizing the protein size is not sufficient, as peptides will
still exhibit similar pharmacological problems, for example,
concerning oral application and development of immune
responses. Small mimetics of IL-4 that are capable to bind
with high affinity to IL-4Ra and compete effectively for IL-4
and IL-13 would be ideal drugs. The modular architecture of
the IL-4/IL-4RaCHR complex with the epitope consisting of
three independently binding clusters suggests an approach
where separate ligands for each cluster are being developed.
Combining these low-affinity ligands in one molecule might
then generate a high-affinity ligand due to adding up of their
binding energies as seen in the clusters of the native protein
ligand IL-4.
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